
ACC Analyst Review 2027: The Last Results Before It Disappears Into Ambuja, and What the Swap Ratio Says
Updated: 17 Nov 2026 • 2:09 pm
Posted by:

ACC Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹1,222.90
- 52-Week High / Low: ₹1,987.00 / ₹1,115.00
- Market Capitalisation: ₹22,950 crore
- P/E Ratio vs Industry P/E: 26.0 vs 36.7
- Latest Quarter (Q2 FY27) Revenue: ₹5,612 crore (standalone, from operations)
- Latest Quarter (Q2 FY27) Net Profit: ₹101 crore (standalone)
Quick Answer: The ACC analyst review 2027 is really a review of the Ambuja merger. ACC's Q2 FY27 standalone profit fell 32% from the June quarter to ₹101 crore on revenue of ₹5,612 crore, and the stock trades near its 52-week low at ₹1,222.90. Brokers are split: Choice (Buy, ₹1,445) and Elara (Accumulate, ₹1,347) see value, while Nomura (Reduce, ₹1,150) does not. Under the scheme, every 100 ACC shares become 328 Ambuja shares, so ACC now trades mainly as a proxy for Ambuja, with the NCLT hearing set for 19 November 2026.
The ACC analyst review 2027 is unusual because the company may not exist as a listed stock by the end of FY27. For anyone tracking the ACC share price target 2027, the key fact is that shareholders approved its merger into Ambuja Cements on 29 September 2026, with more than 95% of ACC votes in favour, and the tribunal hearing is due on 19 November.
ACC closed at ₹1,222.90 on 16 November 2026, about 38% below its 52-week high of ₹1,987 and just 10% above its low of ₹1,115. This ACC analyst review 2027 looks at the September-quarter results, the published targets, the arithmetic of the swap ratio and what it means for the ACC stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the ACC Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Choice Institutional Equities | Buy | ₹1,445 | October 2026 |
| Elara Capital | Accumulate | ₹1,347 | October 2026 |
| Nomura | Reduce | ₹1,150 | July 2026 |
Choice cut its target to ₹1,445 from ₹1,700 after a weak Q2 FY27, citing lower than expected volumes and a sharp fall in profitability, but kept its Buy rating on a valuation of 1.2 times FY28 enterprise value to capital employed. Elara's ₹1,347 note was titled around weak realisation offset by volume and cost benefits, and expects the merger to complete in FY27.
Nomura is the clear bear in the ACC analyst review 2027. After the June quarter it cut its target by 8% to ₹1,150, using 5.5 times forward enterprise value to EBITDA, and said it did not see ACC as the group's preferred vehicle for expansion. With ACC at ₹1,222.90, the verified brokerage range runs from about 6% downside to 18% upside.
Q2 FY27 Results in the ACC Analyst Review 2027
| Metric | Q2 FY27 | Comparison |
|---|---|---|
| Standalone Revenue from Operations | ₹5,612 crore | -2.4% vs Q1 FY27 |
| Standalone Profit After Tax | ₹101 crore | -31.8% vs Q1 FY27 |
| Consolidated EBITDA | ₹508 crore | ₹1,070 crore in Q2 FY26 |
| Consolidated Cement Volume | 9.7 million tonnes | Trade share 78% |
| Premium Products Share of Trade | 47% | +3 pts vs Q1 FY27 |
The quarter extended a long slide. Consolidated EBITDA has fallen every quarter for a year, from ₹1,070 crore in September 2025 to ₹508 crore, and the operating margin dropped to about 7.7% from 17.8%. The September 2025 profit was also lifted by one-off items, so year-on-year profit comparisons look worse than the trend alone.
The ACC analyst review 2027 still found small positives. Trade sales, which carry better prices than bulk institutional orders, rose to 78% of volume, up seven points from a year earlier. Premium products reached 47% of trade sales. ACC also commissioned a 2.4 million tonne grinding unit at Salai Banwa in Uttar Pradesh and 1.0 million tonnes at Kalamboli in Maharashtra.
The Swap Ratio Math in the ACC Analyst Review 2027
Under the scheme approved by both boards in December 2025, Ambuja will issue 328 shares of face value ₹2 for every 100 ACC shares of face value ₹10. That fixes the relationship between the two stocks once the deal closes.
At the 16 November close, 3.28 Ambuja Cements shares at ₹382 were worth about ₹1,253, against ACC's price of ₹1,222.90. ACC therefore trades at a discount of roughly 2.4% to its swap value. That gap reflects the time and approval risk until the scheme becomes effective. When the swap was announced, analysts called it broadly neutral for ACC minority holders.
The practical lesson of this ACC analyst review 2027 is that ACC's future price will track Ambuja's. Any ACC share price target 2027 is, in effect, a view on Ambuja multiplied by 3.28.
How ACC Makes Money
ACC is one of India's oldest cement makers. It sells cement and ready-mix concrete to retail home builders, dealers, infrastructure contractors and companies. Ambuja owns 50.05% directly, and Holderind Investments holds another 4.48%. Like Ambuja, its profit depends on volumes, price per tonne and the cost of fuel, power and freight.
For the ACC analyst review 2027, the key point is that ACC and Ambuja already sit under one group management, which is why the merger is expected to remove duplicated costs. Ambuja has guided that the combined entity should improve margins by at least ₹100 per tonne.
Growth Triggers Behind the ACC Analyst Review 2027
- NCLT approval: a positive outcome at the 19 November 2026 hearing would move the merger close to completion.
- Merger savings: shared brands, plants and freight routes are expected to lift margins.
- New capacity: the 3.4 million tonnes added in Q2 FY27 should support volumes in the busy second half.
- Trade and premium mix: a higher share of retail and premium sales protects realisation.
- Balance sheet: debt to equity of 0.02 means no financial stress.
Key Risks in the ACC Analyst Review 2027
- Falling profitability: four straight quarters of declining EBITDA show the cost problem is not yet solved.
- Merger delay: any setback at the tribunal would leave ACC trading on weak standalone numbers.
- Ambuja risk: because of the swap, a fall in Ambuja's price drags ACC with it.
- Cash flow: operating cash flow was negative ₹1,364 crore in FY26, an unusual figure for a cement company.
- Low returns: return on equity is about 4.3%.
Compare ACC With Cement Peers on the Univest Screener
ACC Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (16 Nov 2026 close) | ₹1,222.90 |
| 52-Week High / Low | ₹1,987.00 / ₹1,115.00 |
| Market Capitalisation | ₹22,950 crore |
| P/E (TTM) vs Industry | 26.0 vs 36.7 |
| Price to Book | 1.11 |
| Book Value per Share | ₹1,101 |
| Return on Equity | 4.27% |
| Debt to Equity | 0.02 |
| FY26 Revenue / Net Profit | ₹26,364 crore / ₹2,137 crore |
A price to book value of about 1.1 is low for a large cement company. The ACC analyst review 2027 suggests the market is valuing ACC on its swap value and weak returns rather than on its assets.
Shareholding Trend
| Holder | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Promoters | 56.69% | 56.69% | 56.69% | 56.69% |
| Foreign Institutions (FII) | 5.05% | 5.93% | 5.83% | 5.75% |
| Domestic Institutions (DII) | 22.55% | 21.61% | 21.13% | 20.97% |
| Public | 15.71% | 15.77% | 16.35% | 16.58% |
In the ACC analyst review 2027 period, domestic institutions cut their stake by about 1.6 points while retail holding rose. The promoter group is unchanged because Ambuja's shares in ACC will simply be cancelled on merger.
What to Watch After the ACC Analyst Review 2027
- 19 November 2026 hearing: the tribunal's decision on the ACC scheme.
- Record date: the date that decides who receives Ambuja shares.
- Swap gap: whether ACC's discount to 3.28 Ambuja shares narrows.
- Q3 FY27 costs: any reversal in the EBITDA decline.
- Ambuja targets: since the ACC share price target 2027 is linked to Ambuja's, revisions there matter most.
Final Word on the ACC Analyst Review 2027
The ACC analyst review 2027 shows a company with weak standalone numbers and a clear exit route. Q2 FY27 profit fell again, EBITDA has halved in a year, and the stock sits close to its low. Yet the swap ratio means ACC holders are heading towards Ambuja shares, and the discount to swap value is only about 2.4%.
For the ACC stock outlook 2027, the tribunal hearing and Ambuja's own cost recovery will matter far more than ACC's next quarter. Univest does not give a buy or sell call on the stock.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the ACC analyst review 2027 show?
It shows weak Q2 FY27 numbers, with standalone profit after tax down 31.8% from the June quarter to ₹101 crore on revenue of ₹5,612 crore. Consolidated EBITDA fell to ₹508 crore from ₹1,070 crore a year earlier. The bigger story is the merger into Ambuja, which shareholders approved on 29 September 2026.
What is the ACC share price target 2027 from brokerages?
Choice has a Buy with ₹1,445 and Elara an Accumulate with ₹1,347, both from October 2026. Nomura has a Reduce with ₹1,150 from July 2026. Against ₹1,222.90, that range runs from about 6% downside to 18% upside.
What is the ACC and Ambuja swap ratio in the ACC analyst review 2027?
ACC shareholders will receive 328 Ambuja shares for every 100 ACC shares once the scheme is effective. At Ambuja's ₹382 close on 16 November 2026, that values one ACC share at about ₹1,253. ACC therefore trades at roughly a 2.4% discount to its swap value.
When will the ACC merger be decided according to the ACC analyst review 2027?
The NCLT has fixed 19 November 2026 for the hearing on the joint company petition. More than 95% of ACC votes and 99% of Ambuja votes supported the scheme. Completion is expected during FY27, subject to regulatory approvals.
Is ACC undervalued on book value?
ACC trades at a price to book of about 1.11 on a book value of ₹1,101 per share. Its P/E of 26.0 is below the industry figure of 36.7. Low return on equity of about 4.3% explains much of the discount.
What risks does the ACC analyst review 2027 highlight?
EBITDA has fallen for four quarters, and FY26 operating cash flow was negative ₹1,364 crore. A delay at the tribunal would leave the stock exposed to weak standalone results. Because of the swap, any fall in Ambuja's share price also pulls ACC down.
What should investors track after the ACC analyst review 2027?
Track the 19 November 2026 NCLT hearing and the record date for the share swap. Watch whether the gap between ACC and 3.28 Ambuja shares narrows. Ambuja's cost per tonne and its brokerage targets will drive ACC's price until the merger is complete.
Recent Articles

Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
17 November 2026

Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
17 November 2026

AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
17 November 2026

A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
63 moons technologies Analyst Review 2027: Cyber Arm Lifts Guidance to ₹600 Crore, But the Group Still Loses Money
Popular this week
5Paisa Capital Analyst Review 2027: Revenue Up 12%, Profit Down 26% and an MTF Book Growing 32%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





